ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Long-term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint
PRESS RELEASE Median follow up nearing 9 years confirms MINDACT as a positive de-escalation study IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MAY 29, 2020 – Agendia, Inc., a world leader in precision oncology Read More
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
PRESS RELEASE Data adds to the growing body of evidence demonstrating the efficacy of Agendia’s MammaPrint® and BluePrint® testing to consistently inform optimal breast cancer treatment planning IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment Irvine, California and Amsterdam, Netherlands, May 07, 2020 Read More
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MARCH 31, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance Read More